This notice is issued in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to grant an exclusive license in the United States to practice the invention described and claimed in Patent No. US 6,706,549, Multi-Functional Micro Electromechanical Devices and Method of Bulk Manufacturing Same, LEW 17,170-1; and Patent No. US 6,845,664, MEMS Direct Chip Attach Packaging Methodologies and Apparatuses for Harsh Environments, LEW 17,256-1, to Spectre Corporation, having its principal place of business in Elyria, Ohio. The fields of use may be limited to mining; farming; undersea exploration; seismic and environmental monitoring; heating, ventilating, and air-conditioning; chemical and petrochemical process control and process automation; water and...
The National Security Agency hereby gives notice of its intent to grant Voltage Networking, LLC a revocable, non-assignable, exclusive, license to practice the following Government-Owned inventions as described in the following: Patent No. 6,835,581 entitled ``Method of coating optical device facets with dielectric layer and device made therefrom''; Patent No. 6,541,288 entitled ``Method of determining semiconductor laser facet reflectivity after facet reflectance modification''; Patent No. 6,760,350 entitled ``Method for measuring gain of photonic inverters''; Patent No. 7,010,187 entitled ``Mode transition-discrimination photonic logic device''; Patent No. 7,599,594 entitled ``Method of fabricating waveguide using sacrificial spacer layer''; Patent No. 7,442,577 entitled ``Method of f...
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license, subject to existing non-exclusive licenses and current non-exclusive license applications under consideration, to practice the inventions embodied in U.S. Provisional Patent Application No. 61/405,668 and PCT Patent Application No. PCT/US2011/057272 and foreign equivalents thereof entitled ``Anti-MAGE-A3 T cell receptors and related materials and methods of use'' (HHS Ref. No. E-236-2010/0); U.S. Provisional Patent Application No. 61/384,931 and PCT Patent Application No. PCT/US2011/051537 and foreign equivalents thereof entitled ``Anti-SSX-2 T cell receptors and relate...
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a worldwide exclusive evaluation option license, to practice the inventions embodied in US patent application 13/180,111, filed July 11, 2011 (HHS Reference<greek-i> E-205-2010/0-US-02), originated from provisional application 61/363,079 filed July 09, 2010, and entitled ``Photosensitizing Antibody Fluorophore Conjugates for Photo- Immunotherapy'' to Aspyrian Therapeutics, Inc., a company incorporated under the laws of the State of Delaware, having its headquarters in San Diego, California. The United States of America is the assignee of the rights of the above inventions. The fi...
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in US Patent application 61/535,668 entitled ``Pseudomonas Exotoxin A with Less Immunogenic B Cell Epitopes'' [HHS Ref. E-263-2011/0-US-01], US Patent application 61/495,085 entitled ``Pseudomonas Exotoxin A with Less Immunogenic T Cell Epitopes'' [HHS Ref. E-174-2011/0-US-01], US Patent application 61/483,531 entitled ``Recombinant Immunotoxin Targeting Mesothelin'' [HHS Ref. E-117-2011/0-US-01], U.S. Patent Application 61/241,620 entitled ``Development of an Immunotoxin in Which All B-Cell Epitopes Have Been Removed and Which H...
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in Patent Applications USSN 61/021,596, filed Jan 16, 2008; 61/023,341, filed Jan 24, 2008; PCT/US2009/031329, filed Jan 16, 2009; and USSN 12/838,292, filed Jul 16, 2010; entitled ``Influenza DNA Vaccination and Methods of Use Thereof'', by Rao et al (NIAID/VRC) (E-050-2008/0,1,2,3), to Newport Laboratories having a place of business in 1520 Prairie Drive, Worthington, MN 56187. The patent rights in this invention have been assigned to the United States of America.
This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention (CDC), Technology Transfer Office, Department of Health and Human Services (DHHS), is contemplating the grant of a worldwide, exclusive license (excluding the nonexclusively licensed field of use entitled ``Use of P4 as either a carrier and/or immunoenhancer in a polysaccharide vaccine conjugate for prevention of Streptococcus pneumonia infection in humans'') to practice the inventions embodied in the patent application referred to below to Viper Therapeutics, having a place of business in Atlanta, Georgia. The patent rights in these inventions have been assigned to the government of the United States of America. The patent(s) to be licensed are:
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents to Jennerex Biotherapeutics (``Jennerex'') located in San Francisco, CA, USA. Intellectual Property: 1. U.S. Patent No. 7,045,313 issued May 16, 2006 entitled, ``Recombinant Vaccinia Virus Containing a Chimeric Gene Having Foreign DNA Flanked by Vaccinia Regulatory DNA'' [HHS Ref. No. E-552-1982/2-US- 03]; 2. U.S. Patent No. 7,015,024 issued March 21, 2006 entitled, ``Compositions Containing Recombinant Poxviruses Having Foreign DNA Expressed under the Control of Poxvirus Regulatory Sequence'' [HHS R...
The Department of the Navy hereby gives notice of its intent to grant to Cobalt Technologies, Inc., a revocable, nonassignable, partially exclusive license in the United States to practice the Government-owned inventions described in the following: patent application 61/562231: Water and Contaminants Removal From Butanol Fermentation Solutions and/or Broths Using a Brine Solution, filed on November 21, 2011.//patent application 61/527943: Dehydration of Bio- Derived Alcohols to Alkenes Using Highly Selective Catalysts, filed on August 26, 2011.//patent application 12/511796: Diesel and Jet Fuels Based on the Oligomerization of 1-Butene, filed on July 29, 2009.// patent application 12/769757: Turbine and Diesel Fuels and Methods of Making the Same, filed on April 29, 2010.//patent applic...
ver las páginas en versión mobile | web
ver las páginas en versión mobile | web
© Copyright 2012, vLex. All Rights Reserved.
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
Other interesting searches:
Independent Studies | cfr 1500 3 | Carpenter Sas | marketplace sap | national service secretariat | medianeria forzosa | jueces legos | ley 20 261 | ressources definition | Servizio sanitario nazionale
